Protara Therapeutics (TARA) investor relations material

Introduction and agenda

• The event provided an overview of the lymphatic malformations (LMs) program, recent FDA interactions, and plans for a BLA submission for TARA-002 in the second half of 2027.

• The session included presentations from clinical investigators, R&D, commercial, and finance leaders, followed by a Q&A.

• The agenda included case studies, market overview, and a Q&A session.

• The event focused on TARA-002 as a targeted therapy for LMs, highlighting unmet needs and clinical progress.

KOL background and credentials

• Dr. Naiem Nassiri is a board-certified vascular and endovascular surgeon, founder of a leading vascular malformations center, and adjunct Yale faculty.

• Dr. Jesse G.A. Jones is a board-certified interventional neuroradiologist and associate professor at UAB, managing complex vascular anomalies.

• Presenters included Jesse G.A. Jones, MD (University of Alabama), Naiem Nassiri, MD (Yale), and Jacqueline Zummo, PhD.

Market insights and analysis

• LMs are rare, congenital malformations with significant morbidity and no FDA-approved therapies.

• Approximately 1,500 new LM cases are diagnosed annually, with up to 80,000 prevalent cases in the U.S.; 20,000 have macrocystic or mixed cystic disease.

• Macrocystic and mixed cystic LMs represent ~79% of cases, with an estimated $1bn+ addressable market.

• Most patients are diagnosed in the community and referred to vascular anomaly centers; top 100 accounts treat ~80% of LM patients.

• Current treatments include surgery and sclerotherapy, but both have high recurrence and safety concerns.